Status:
ACTIVE_NOT_RECRUITING
Rehabilitation for People With Advanced Cancer
Lead Sponsor:
University Health Network, Toronto
Conditions:
Advanced Breast Cancer
Advanced Colorectal Cancer
Eligibility:
All Genders
18+ years
Phase:
NA
Brief Summary
The proposed study is a Phase II, feasibility, randomized controlled preference based study. This will be conducted in Vancouver and Toronto and includes breast and colorectal cancers.
Detailed Description
Cancer rehabilitation interventions that address common impairments and focus on maintaining or reducing the rate of functional decline are greatly needed for the growing population of cancer survivor...
Eligibility Criteria
Inclusion
- Age 18 years or older
- Diagnosed with locally advanced incurable or metastatic breast or colorectal cancer
- Eastern Cooperative Oncology Group (ECOG) performance status of 0-2
- Fully independent with ambulation and transfers with or without ambulatory assistance
- Palliative Performance score of \>70 (moderate predictive power estimating life expectancy \>6 months)
- Receiving first or second line anti-cancer treatments in the metastatic / incurable setting (a relative proxy for expected survival \>6 months)
- Medical clearance to participate from treating physician
Exclusion
- Wheelchair level community ambulation
- Moderate or severe non-cancer pain (\>6 out of 10 on visual analog scale)
- Moderate or severe cancer bone pain (\>Gr 2 bone pain (i.e., moderate pain limiting instrumental ALDs or worse) as measured on CTCAE (see below))
- Severe or uncontrolled depressive symptoms (\>20 on PHQ-9)
- Known neurological conditions influencing cognition and preventing safe or appropriate engagement with self-management and exercise recommendations (e.g., dementia, traumatic brain injury, or brain metastasis influencing cognition or causing moderate-to-severe motor-sensory-coordination). Best determined by the referring physician or nurse practitioner.
- Unable to communicate sufficiently in English to complete intervention, questionnaires, and consent.
- Unwillingness to be randomized, participate in a group intervention, or attend individual physical assessments.
- Inability to operate videoconferencing if preference is virtual programming.
Key Trial Info
Start Date :
December 2 2022
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
January 30 2026
Estimated Enrollment :
111 Patients enrolled
Trial Details
Trial ID
NCT05424068
Start Date
December 2 2022
End Date
January 30 2026
Last Update
December 3 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Princess Margaret Cancer Centre
Toronto, Ontario, Canada, M5G2M9